Transcatheter aortic valve implantation (TAVI) is now an established alternative treatment for patients with severe calcific aortic stenosis deemed at high risk for conventional surgical aortic valve replacement1. Tens of thousands of procedures have been performed worldwide since the first implant by Cribier in 2002. As the number of procedures continues to increase rapidly, the procedures and devices have evolved, leading to improvements in patient outcomes. Enthusiasm for the technology has translated into increased use in the treatment of failing bioprosthetic valves. This use was first reported by Wenaweser and colleagues in 20072 and offers an alternative to high-risk redo ...
CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR
August 7, 2020